201 related articles for article (PubMed ID: 18297267)
21. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
Langan KM; Jacob J; Li J; Nation RL; Bellomo R; Howden B; Johnson PD
Crit Care Resusc; 2014 Sep; 16(3):190-6. PubMed ID: 25161021
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.
Kuti JL; Nightingale CH; Knauft RF; Nicolau DP
Clin Ther; 2004 Apr; 26(4):493-501. PubMed ID: 15189746
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
Pai MP; Cojutti P; Pea F
Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.
Thalhammer F; Hörl WH
Clin Pharmacokinet; 2000 Oct; 39(4):271-9. PubMed ID: 11069213
[TBL] [Abstract][Full Text] [Related]
27. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.
Jaruratanasirikul S; Sriwiriyajan S; Punyo J
Antimicrob Agents Chemother; 2005 Apr; 49(4):1337-9. PubMed ID: 15793108
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].
Bo SN; Li HL; Zhu X; Yao GQ; Hu YF; Zhai SD; Lu W; Wang SY; Xu YZ; He B
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Mar; 24(3):145-8. PubMed ID: 22401158
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
Dandekar PK; Maglio D; Sutherland CA; Nightingale CH; Nicolau DP
Pharmacotherapy; 2003 Aug; 23(8):988-91. PubMed ID: 12921245
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion.
Langgartner J; Lehn N; Glück T; Herzig H; Kees F
Chemotherapy; 2007; 53(5):370-7. PubMed ID: 17785973
[TBL] [Abstract][Full Text] [Related]
32. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
Shekar K; Fraser JF; Taccone FS; Welch S; Wallis SC; Mullany DV; Lipman J; Roberts JA;
Crit Care; 2014 Dec; 18(6):565. PubMed ID: 25636084
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis.
Kielstein JT; Czock D; Schöpke T; Hafer C; Bode-Böger SM; Kuse E; Keller F; Fliser D
Crit Care Med; 2006 Jan; 34(1):51-6. PubMed ID: 16374156
[TBL] [Abstract][Full Text] [Related]
34. Meropenem in children receiving continuous renal replacement therapy: clinical trial simulations using realistic covariates.
Nehus EJ; Mouksassi S; Vinks AA; Goldstein S
J Clin Pharmacol; 2014 Dec; 54(12):1421-8. PubMed ID: 25042683
[TBL] [Abstract][Full Text] [Related]
35. Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.
Wittau M; Scheele J; Kurlbaum M; Brockschmidt C; Wolf AM; Hemper E; Henne-Bruns D; Bulitta JB
Antimicrob Agents Chemother; 2015 Oct; 59(10):6241-7. PubMed ID: 26248353
[TBL] [Abstract][Full Text] [Related]
36. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
[TBL] [Abstract][Full Text] [Related]
37. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
[TBL] [Abstract][Full Text] [Related]
38. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach.
Pea F; Viale P; Cojutti P; Furlanut M
Antimicrob Agents Chemother; 2012 Dec; 56(12):6343-8. PubMed ID: 23045356
[TBL] [Abstract][Full Text] [Related]
39. β-lactam antibiotic concentrations during continuous renal replacement therapy.
Beumier M; Casu GS; Hites M; Seyler L; Cotton F; Vincent JL; Jacobs F; Taccone FS
Crit Care; 2014 May; 18(3):R105. PubMed ID: 24886826
[TBL] [Abstract][Full Text] [Related]
40. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
